Anti-Mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1, Mouse IgG2c) | PA007162.m2c

Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1) | PA007162.m2c Syd Labs

Anti-Mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1, Mouse IgG2c) | PA007162.m2c

$400.00

In stock
Catalog No.: PA007162.m2c | Isotype: Mouse IgG2c, Kappa | In Vivo Grade

$400.00

In vivo anti-mouse PD-1 antibody (mouse IgG2c, clone RMP1-14.1) — a recombinant mAb that pairs the identical antigen-binding variable region of the classic rat clone RMP1-14 with a mouse IgG2c kappa constant region.

Its mouse-native IgG2c Fc retains intact effector function (ADCC/CDC), making it the isotype-matched choice for C57BL/6 (Igh-1b) strains and related backgrounds, including the widely used MC38 and B16-F10 syngeneic models.

Produced in mammalian cells; >95% purity (SDS-PAGE), <1 EU/mg endotoxin (LAL).

Clear
View cart
Catalog No. PA007162.m2c
Product Name In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c Kappa
Data Sheet 📄 Download Product Data Sheet (PDF)
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Synonyms Anti-mPD-1 mAb (Mouse IgG2c), Clone RMP1-14.1 Mouse IgG2c
Summary The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2c Kappa Monoclonal Antibody (Clone RMP1-14.1) was produced in mammalian cells.
Clone RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14)
Isotype mouse IgG2c, kappa
Applications immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Immunogen The original rat hybridoma (clone name: RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells.
Form Of Antibody 0.2 μM filtered solution of 1x PBS.
Endotoxin Less than 1 EU/mg of protein as determined by LAL method.
Purity >95% by SDS-PAGE under reducing conditions.
Shipping The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2c Kappa Monoclonal Antibody (Clone RMP1-14.1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.
Note Recombinant anti-mouse PD-1 / CD279 monoclonal antibodies, which retain the same variable region sequence as the rat anti-mouse PD-1 monoclonal antibody (clone RMP1-14) with a rat IgG2a constant region, are expressed in mammalian cells. Recombinant rat, chimeric mouse, and Fc-silent LALAPG mutant versions are also available.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

References of Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1, mouse IgG2c)

Selected publications using anti-mouse PD-1 (clone RMP1-14) in mouse IgG2c-relevant settings — including syngeneic C57BL/6 (Igh-1b) tumor models such as LLC, Hepa1-6, HCA-1 and DEN, and studies on Fc effector function in PD-1⁺ cell depletion. All studies used the RMP1-14 variable region; where the parental rat IgG2a or another mouse isotype was used, the identical antigen-binding variable region makes the functional conclusions directly applicable to this mouse IgG2c κ format.

1. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy
Masakazu Sato, et al. Cancer Med 2023. doi: 10.1002/cam4.5696
“Angiogenic inhibitors combined with anti-PD-1 blockade has become a standard choice for multiple advanced malignancies. We demonstrated that pre-treatment with anti-angiogenic agents improves tumor vascular normalization. This optimal pre-administration schedule enhances the subsequent therapeutic efficacy of anti-mouse PD-1 antibody treatment in syngeneic models.”

2. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
Renata DeAzevedo, et al. J Immunother Cancer 2024. doi: 10.1136/jitc-2024-009690
“Hepatocellular carcinoma often creates an immune-excluded microenvironment resisting single-agent treatments. We showed that selective type I MET inhibition reverses immune exclusion patterns. Combining this targeted approach with anti-PD-1 antibody interventions triggers complete rejection in a high percentage of murine models.”

3. Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Tao Zhang, et al. Protein Sci 2023. doi: 10.1002/pro.4741
“Investigating the roles of chronic PD-1+ populations requires reliable depletion methods. We engineered a diphtheria toxin-based immunotoxin architecture targeting mouse PD-1 structures. This molecule mediates rapid, highly specific systemic elimination of active PD-1-positive subgroups inside immunocompetent strains.”

For more technical references or data sheets regarding the Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1) formats, including options from Syd Labs, please contact our scientific support team at message@sydlabs.com.

Other Formats

All variants below share identical RMP1-14.1 variable region sequences and mouse PD-1 (CD279) binding specificity. They differ only in Fc isotype and Fc effector function — choose the format that matches your experimental readout and mouse strain.

Catalog No. Isotype Fc Effector Function Host / Reactivity Applications
PA007162.r2a Rat IgG2a, kappa Intact (ADCC / CDC competent) Rat / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2a Mouse IgG2a, kappa Intact (ADCC / CDC competent) Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2c Mouse IgG2c, kappa Intact (ADCC / CDC competent) Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m1 Mouse IgG1, kappa Low effector function Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2aLA Mouse IgG2a-L234A L235A P329G (LALAPG), kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silenced neutralization
PA007162.m2cLA Mouse IgG2c-L234A L235A P329G (LALAPG), kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silenced neutralization
PA007162.m1DA Mouse IgG1-D265A, kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silent neutralization
PA007162.rt Rabbit IgG Rabbit Fc (non-mouse effector) Rabbit / Mouse IHC, FC, in vitro and in vivo functional assays

How to choose a format: Use an intact-Fc format (r2a, m2a, m2c, m1) when your readout may involve Fc-mediated effector activity, and note that mouse IgG2c matches the C57BL/6 (Igh-1b) allotype commonly used in MC38 and B16-F10 models, while mouse IgG2a matches BALB/c (Igh-1a) backgrounds such as CT26. Use an Fc-silenced format (m1DA, m2aLA, m2cLA) when you need pure PD-1 blockade without Fc-receptor engagement or ADCC/CDC confounding.

Ushelf Advisor

Research Reference Only — Compiled from peer-reviewed literature and Ushelf product specifications. Please verify critical parameters (dosing, working dilutions, buffer conditions) against the primary references, or confirm with our technical support before finalizing your experimental design.

Last updated: October 22, 2026.

Q: What is the difference between PA007162.m2c and traditional rat IgG2a anti-mouse PD-1 antibodies like PA007162.r2a?

PA007162.m2c retains the identical rat-derived antigen-binding variable region of clone RMP1-14, but replaces the rat IgG2a constant region with a wild-type mouse IgG2c constant region. This chimeric design minimizes host immune responses against foreign rat Fc domains in mouse models while preserving native mouse Fc effector functions like ADCC and CDC activities.

Q: Why choose a mouse IgG2c isotype variant (PA007162.m2c) over mouse IgG2a for in vivo studies?

C57BL/6, C57BL/10, SJL, and NOD mouse strains express the IgG2c gene (Igh-1b allele) rather than IgG2a (Igh-1a allele found in BALB/c and C3H). Utilizing a mouse IgG2c format in these specific strains provides an isotype-matched Fc profile that avoids unwanted anti-isotype immune responses and closely mimics endogenous Fc–FcγR interactions during checkpoint blockade.

Q: Is PA007162.m2c suitable for in vivo preclinical research?

Yes, this anti-mouse PD-1 monoclonal antibody is produced in mammalian cells as an in vivo grade reagent with high purity (>95% by SDS-PAGE) and ultra-low endotoxin levels (<1 EU/mg by LAL method). It is widely applied for in vivo PD-1 checkpoint blockade in syngeneic tumor models like MC38 and B16-F10, as well as flow cytometry (FC) and immunohistochemistry (IHC).

Q: What specific clone characteristics and origin does PA007162.m2c have?

Designated as clone RMP1-14.1, this recombinant anti-mouse PD-1 monoclonal antibody shares identical variable region sequences with the classic rat anti-mouse PD-1 clone RMP1-14, which was originally generated by immunizing rats with mouse PD-1-transfected BHK cells.

Q: Which isotype control should I use with PA007162.m2c in C57BL/6 mouse models?

A matching mouse IgG2c, kappa isotype control formulated at equivalent purity and buffer conditions is strongly recommended for in vivo functional assays and flow cytometry in C57BL/6 or related strains to accurately distinguish target-specific PD-1/CD279 inhibition from non-specific Fc receptor binding.

Q: Does PA007162.m2c possess intact Fc effector function compared to Fc-silenced variants like PA007162.m2cLA?

Yes, unlike Fc-silent LALAPG mutants (PA007162.m2cLA), PA007162.m2c retains native mouse IgG2c Fc gamma receptor binding and complement engagement, making it suitable for studies where active immune engagement, Fc-mediated cytotoxicity, and intact effector capabilities are required alongside PD-1 blockade.

Q: How do I choose between mouse IgG2a (PA007162.m2a) and mouse IgG2c (PA007162.m2c) for my research?

You should select the antibody isotype based directly on your experimental mouse strain background: use mouse IgG2c (PA007162.m2c) for C57BL/6, C57BL/10, SJL, or NOD mice, and select mouse IgG2a (PA007162.m2a) for BALB/c, C3H, or DBA/2 mice to ensure optimal strain-matched compatibility.

Q: Are bulk packaging or carrier-protein free custom formulations available for PA007162.m2c?

Yes, bulk quantities and custom carrier-protein free formulations can be customized upon request to meet large-scale in vivo preclinical study protocols and specific buffer requirements. Contact technical support to discuss batch availability and customized production needs.